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RESUmo
A fenitoína é um anticonvulsivante que 
vem sendo empregado na cicatrização de 
ferida. Os objetivos desta pesquisa foram: 
descrever como a produção científica apre-
senta o uso da fenitoína como agente cica-
trizante e discutir sua aplicabilidade em fe-
ridas. Foi realizada, para tanto, revisão in-
tegrativa da literatura e análise pela hierar-
quia das práticas baseadas em evidências. 
Assim, analisaram-se 18 artigos que testa-
ram a intervenção em feridas como úlceras 
de perna, por hanseníase, pé diabético, 
úlceras por pressão, tróficas, ferimentos 
de guerra, queimaduras, preparo da área 
receptora de enxerto, radiodermites e pós-
extração de nevos melanocíticos. Uso sistê-
mico da fenitoína no tratamento de fístulas 
e a hipótese do uso tópico no tratamento 
do vitiligo foram achados. Conclui-se que a 
fenitoína tópica é uma evidência científica. 
No entanto necessita-se de pesquisas ro-
bustas que sustentem o uso protocolar da 
fenitoína como mais uma opção de agente 
cicatrizante na prática clínica.
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AbStRAct
Phenytoin is an anticonvulsant that has 
been used in wound healing. The objec-
tives of this study were to describe how 
the scientific production presents the use 
of phenytoin as a healing agent and to 
discuss its applicability in wounds. A lit-
erature review and hierarchy analysis of 
evidence-based practices was performed. 
Eighteen articles were analyzed that 
tested the intervention in wounds such 
as leprosy ulcers, leg ulcers, diabetic foot 
ulcers, pressure ulcers, trophic ulcers, war 
wounds, burns, preparation of recipient 
graft area, radiodermatitis and post-ex-
traction of melanocytic nevi. Systemic use 
of phenytoin in the treatment of fistulas 
and the hypothesis of topical use in the 
treatment of vitiligo were found. In conclu-
sion, topical use of phenytoin is scientifi-
cally evidenced. However robust research 
is needed that supports a protocol for the 
use of phenytoin as another option of a 
healing agent in clinical practice. 
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RESUmEn 
La fenitoína es un anticonvulsivo que se 
utiliza en la cicatrización de heridas. Los 
objetivos de esta investigación fueron: 
describir cómo la producción científica 
presenta el uso de la fenitoína como agen-
te cicatrizante y discutir su aplicabilidad 
en las heridas. Se realizó una revisión in-
tegradora de la literatura y el análisis por 
la jerarquía de las prácticas basadas en las 
evidencias. Se analizaron 18 artículos que 
probaron la intervención en heridas como 
úlceras en la pierna por hanseniasis, pie 
diabético, úlceras por presión, tróficas, he-
ridas de guerra, quemadura, preparación 
de la zona a injertar, radiodermitis y post 
extracción de nevos melanocíticos. Se en-
contró el uso sistémico de la fenitoína en 
el tratamiento de fístulas y la hipótesis del 
uso tópico en el tratamiento del vitíligo. Se 
concluye que la fenitoína tópica es una evi-
dencia científica. Sin embargo, se necesita 
de investigaciones sólidas que sustenten 
el uso protocolar de la fenitoína como una 
opción más, considerándolo un agente ci-
catrizante en la práctica clínica.
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intRodUction
Phenytoin is an anticonvulsant drug available in the 
market since 1937. It acts by blocking neuronal excitation 
by binding to sodium channels at rest, preventing them 
from becoming functional and generating excitatory ac-
tion potentials(1). The possibility of its use as a healing 
agent began to be investigated by primary experimental 
studies in the field of dentistry, when, in 1939, hypergran-
ulation of gingival tissue was recognized as its adverse ef-
fect, which suggested possible use of this drug as a heal-
ing agent in wounds(2-3).
The exact mechanism through which phenytoin induc-
es tissue healing is unclear, and the ways to apply it for 
this purpose are not standardized(4). However, the dissem-
ination of satisfactory results of empirical research about 
the performance of phenytoin in healing chronic wounds 
such as pressure, vascular and diabetic ulcers, has caught 
the attention of nurses that deal with this theme, such as 
stomatherapy expert nurses.
Phenytoin is a low-cost drug, and the study of its heal-
ing capacity for clinical practice is important. However, 
there is a need for research that can elucidate the subject 
and encourage its discussion in our context. Therefore, 
this research chose as the subject of investigative interest 
the scientific production on the therapeutic potential of 
phenytoin in the wound healing process in humans. The 
objectives were to describe how the scientific production 
presents the use of phenytoin as a healing agent and to 
discuss its applicability in wounds.
mEtHod
An integrative literature review from 2003 to 2011 was 
performed. The temporal limit is justified by the publica-
tion of the study The clinical effect of topical phenytoin on 
wound healing: a systematic review by the British Journal 
of Dermatology(3), which, although published in 2007, ad-
opted temporal delimitation of 1963 to the middle of the 
year 2003.
Inclusion criteria were: a) articles that discussed the 
use of phenytoin in healing any kind of tissue injury in hu-
mans, b) available in Portuguese, English or Spanish.
The integrative review was divided into six stages: the 
first stage was the selection of the review question, which 
characterizes the definition of the subject to be studied; 
second stage was the selection of the bibliography. The 
third stage was the categorization of studies considering 
the data collection form validated by Ursi(5).
The fourth stage was the review of inclusion criteria, 
critical reading, and systematic data analysis. The fifth 
step was interpretation of the results, discussion, organi-
zation and tabulation of information. And the sixth step 
was the presentation of the review to enable the critical 
analysis of the findings by the reader, as recommended by 
the method adopted.
The guiding question of the review was: How is the 
healing potential of phenytoin presented in the scientific 
literature regarding its clinical applicability in human 
wounds. The selection of articles occurred in mid-April of 
2012, in the following databases: Medical Literature Anal-
ysis and Retrieval System Online (MEDLINE), PubMed, 
Cochrane and Latin American and Caribbean Literature 
on Health Sciences (LILACS), accessed through the Virtual 
Health Library (VHL) portal. For the search of articles in 
the Latin American database, the descriptor phenytoin 
and the term wounds were used, and in the American 
databases, the descriptor phenytoin combined with the 
words wound; wound healing was used.
In MEDLINE, the descriptor phenytoin, when refined 
by combining it with the word wound using the boolean 
operator AND retrieved 92 studies. When the term wound 
was combined with wound healing using the Boolean op-
erator AND, the research retrieved 82 studies. After du-
plicate exclusion, on a first analysis, considering titles and 
abstracts when available, 36 articles were selected. Re-
peating the same search model in PubMed and Cochrane, 
studies were duplicated, therefore no articles were in-
cluded in this stage.
In the Latin American database, the descriptor phe-
nytoin refined with the term wounds retrieved two stud-
ies, and one article was selected. The combination of the 
descriptor with the term wound healing retrieved no in-
dication. Therefore, the preliminary selection was com-
posed of 37 articles, which were categorized by the form 
adopted in this review. The categorization pointed to the 
need for full reading of the selected material, the texts 
being downloaded online and/or requested from institu-
tional libraries. After a complete reading, 18 articles were 
included in the research, advancing to the fifth stage of 
this integrative review.
Data analysis used the level of evidence hierarchy, 
adopting standardized classification of evidence from one 
to seven: one corresponds to systematic review that ex-
amined randomized controlled trials, considered to be 
the type of research with highest reliability and scientific 
validity; Two: randomized clinical trial (RCT): with com-
parable groups and randomly divided in order to test in-
terventions; Three: cohort study: study with observation 
and follow-up of  the development of situations and/or 
injuries to the groups exposed to risks; Four: case-control 
study: interventions are applied to a given group, and the 
results are compared with a group which did not receive 
the intervention and serves as a parameter for compari-
son; Five: case series: the intervention is performed in 
several people and the outcomes analyzed and discussed 
in a particularized observational manner; Six: expert opin-
ion: people considered experts opine on the possible in-
terventions and the possible outcomes expected using 
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empirical work experience, without testing the mentally 
prepared hypotheses; Seven: Preclinical studies - studies 
conducted through experimentation on live animals or in 
controlled situations and laboratory test tubes.
From these criteria, force of evidence can be classified 
as strong, moderate and weak: research levels 1 and 2 
have strong research evidence, levels 3 and 4 have moder-
ate research evidence and levels 5 and 7 have weak research 
evidence. Beyond the force level, evidence has a degree of 
recommendation generated by the following rating: A - when 
the search result recommends the intervention, B - when the 
search result is not conclusive, and C - when the search result 
contraindicates the intervention(6). This classification was ad-
opted in this study.
RESULtS
The analysis of 18 articles in this literature review 
shows evidence of topical phenytoin as a healing agent 
applied to a range of chronic wounds and also acute 
wounds, in addition to its systemic use in the manage-
ment of fistulas of the gastrointestinal tract. Beneficial 
effects published urged the creation of the hypothesis of 
its topical use in the treatment of vitiligo, expanding the 
options for clinical investigation in other diseases that af-
fect the skin, other than wounds themselves.
The Middle Eastern countries stand out in the scientif-
ic literature regarding the healing potential of phenytoin 
in humans, followed by: the United Kingdom, India, China 
and Brazil.
When considering the level of evidence and degree of 
recommendation, the United Kingdom is again highlighted, 
with two important strong-evidence studies published by the 
same author. Altogether the scientific production is typically 
published in English and performed in the academic medi-
cal area, especially the area of dermatological medicine, fol-
lowed by endocrinology, surgery, neurology and dentistry. 
There was scientific production published in Portuguese, de-
veloped in the area of oncology nursing, as shown in Chart 1.
In the period of time delimitation studied in this integra-
tive review, every year there was scientific production at an 
average two to three articles/year, and the year 2011 had 
four articles. This facet indicates an increased investigative 
interest on the theme in question.
Chart 1 - Studies that investigated the healing potential of phenytoin categorized by the hierarchy of scientific evidence - Rio de Janeiro 2012
Title/Reference (*) Year/Country
Design/
Research N Interventions Outcomes
Evidence
/recomen-
dation
The clinical effect of 
topical phenytoin on 
wound healing: a sys-
tematic review(3)
2007
United 
Kingdom
Systematic re-
view/ 14 RCT
Unspecified topical use in sev-
eral types of wounds
Moderate evidences for the use in 
leg, leprosy, chronic, ulcers, dia-
betic foot. Limited evidences for 
the use in burns and war wounds
1/A
A systematic review of 
randomized controlled 
trials of treatments for 
inherited forms of epi-
dermolysis bullosa(7)
2008
United 
Kingdom
Systematic 
review /5 RCT
Oral pill 5mg/kg/day for Epider-
molysis bullosa wound healing 
No significant results compared to 
other interventions investigated 1/C
Nonhealing wounds – a 
therapeutic dilema(8)
2003
India
RCT/N 150
divided into 3 
groups: human 
placenta extract, 
phenytoin and 
saline
100 mg pill macerated apllied 
1x/day in pressure, diabetic foot, 
leprosy and venous ulcers
Phenytoin group: healing in 48% 
cases, with full healing around 
the 21st day in group treatment 
and around the 45th day in group 
control
2/A
The use topical phenyto-
in for healing of chronic 
venous ulcerations(9)
2011
Egypt
RCT/
N104
divided into 
study group 
(N54) and
control (N50)
Manipulated lotion (1gr de 
phenytoin+ 25 mL lipossomal 
base) applied 1x/day for 8 weeks 
in  venous ulcers
Full healing in N35 of the study 
group and in N26 of the control 
group. ↓ of ulcer surfaces was 
higher in the study groups. 
Burning sensation referred by N4 
(7.4%)
2/A
Topical phenytoin 
versus eusol in the treat-
ment of non- malignant 
chronic leg ulcers(10)
2003
Tanzania
RCT/N 102
testing two 
interventions: 
Phenytoin (N50) 
x Eusol (N52)
Macerated pills appliedto 
traumatic, inflammation, venous, 
diabetic, trophic ulcers, bites 
and burns
↓ pain, draining,
and ↑ granulation tissue and 
healing more significant in the 
phenytoin group
2/A
Continued...
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...Continuation
Continued...
Title/Reference (*) Year/Country
Design/
Research N Interventions Outcomes
Evidence
/recomen-
dation
Topical phenytoin suspen-
sion and normal saline in 
the treatment of leprosy tro-
phic ulcers: a randomized,
double-blind, comparative 
study(11)
2004
India
RCT/N45
comparing topi-
cal phenytoin 2% 
and
4%
Gauze moistened with 100mg 
or 200mg pills dissolved in 5 
mL solution of saline applied in 
leprosy ulcers 1x/day
Effectiveness in both cases, no 
significant difference 2/A
Topical phenytoin solution 
for treating pressure ulcers: 
a prospective, randomized, 
double-blinded clinical 
trial(12)
2007
India
RCT/N 28
Intervention and 
control groups 
(saline) with 
assessment of 
the systemic 
phenytoin absor-
tion rate
Gauze moistened with diluted 
intravenous solution 50mg/ml 
in saline (9 mL) topically ap-
plied on pressure ulcers stage II 
1x/day for 15 days
Healing evaluated by PUSH 
method evidencing slightly faster 
healing than the control group. 
Serum concentrations less than 
0.2 ug/mL indicating negligible 
systemic absorption 
2/A
A randomized clinical 
trial comparing hydrocol-
loid, phenytoin and simple 
dressing for the treatment of 
pressure ulcers(13)
2004
Iran
RCT/N83
paraplegic with 
91 ulcers
dividided in 3 
groups: hydrocol-
loid, phenytoin 
and saline
Phenytoin cream applied 1x/day 
for 8 weeks
Hydrocolloid was more effective 
in healing with no significant 
differences between saline and 
phenytoin
2/B
A randomized clinical 
trial comparing hydrocol-
loid, phenytoin and simple 
dressing for the treatment of 
pressure ulcers(13)
2004
Iran
RCT/N83
paraplegic with 
91 ulcers
dividided in 3 
groups: hydrocol-
loid, phenytoin 
and saline
Phenytoin cream applied 1x/day 
for 8 weeks
Hydrocolloid was more effective 
in healing with no significant 
differences between saline and 
phenytoin
2/B
Short report: treatment the 
effect of topical phenytoin 
on healing in diabetic foot 
ulcers: a randomized con-
trolled trial(14)
2011
United 
King-
dom
RCT/N65
31N in the inter-
vention group 
and N34 in the 
control group
Measuring of the 
serum level of 
phenytoin up to 
16 weeks
Phenytoin alginate applied 
6mg/cm
1x/day
No significant difference among 
the groups Minimum systemic 
absorbance
2/C
Two percent topical phe-
nytoin sodium solution in 
treating pyoderma
grangrenosum: a cohort 
study(15)
2010
Sri 
Lanka Cohort study/N6
Gauze moistened in a solution 
of 2% phenytoin and placed on 
resistant pyoderma gangreno-
sum wounds, 1x/day for 4 
weeks
4 patients had fulls wound healing 
and 2 had partial resolution 3/A
Assessment of the effect 
of phenytoin on cutaneous 
healing from excision of 
melanocytic nevi on the 
face and on the back(16)
2010
Brazil
Longitudinal 
case-control/N 
100 patients
with 200 lesions
Phenytoin cream 0.5% applied 
daily on injuries from removal 
of face and neck nevi
Lesions had more bleeding, 
exudate and hyperemia. ↑ edges, 
intense epithelialization and less 
healing time and good cosmetic 
effects on the scar
4/A
Wound bed preparation with 
10 percent phenytoin oint-
ment increases the take of 
swplit-hickness skin graft in 
large diabetic ulcers(17)
2006
Jordâ-
nia
Case-control with 
hystological as-
sessment /N16
Phenytoin 10% ointment based 
on vaseline applied 1x/day 
in wound bed preparation of 
diabetic foot ulcers for grafting, 
for up to 8 weeks
100% survival of the grafting in 
12
patients, 80-90% in 3
and 60% in 1 patient
4/A
The impact of topical phe-
nytoin on recalcitrant
neuropathic diabetic foot 
ulceration(18)
2009
Egypt Prospective case series/N 32
Aerosol phenytoin 2% applied 
directly to diabetic foot wounds 
1x/day in addition to usual 
treatment (instrumental debride-
ment and cleansing with saline) 
for 8 weeks
50% patients had ↓ of wound size 
(mean 18.3% to 38.6% of the 
wound area)
5/A
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...Continuation
Title/Reference (*) Year/Country
Design/
Research N Interventions Outcomes
Evidence
/recomen-
dation
Phenytoin-induced lym-
phocytic chemotaxis, an-
giogenesis and accelerated 
healing of decubitus ulcer in 
a patient with stroke(19)
2004
Greece
Comparative 
case study with 
biopsy analysis 
of 2 wounds in 1 
patient
5mL IV phenytoin (250mg) 
apllied on a pressure ulcer in 
sacral region in a paraplegic 
patient1x/day for 2 weeks as-
sociated with standard treatment 
(debridement, antiseptic and dry 
gauze)
Faster healing by stimulating 
lymphocyte chemotaxis and super 
regulation of angiogenesis only 
in lesions treated with topical 
phenytoin
5/A
Therapeutic potential of  
phenyotin in radiodermitis 
healing(4)
2007
Brazil Case report/N1
1mL phenyotin (50mg) dilluted 
in 5ml saline applied 2x/day in 
radiodermitis wound stage III 
with 5x3cm in cervical region 
for 13 days
Complete epithelialization which 
enabled cervical motion before 
impossible
5/A
Does phenytoin improve 
the healing of gastintestinal 
fistulas?(20)
2011
Saudi 
Arabia
Case report/N2
300mg/day pills for10 days via 
nasogastric tube in patients with 
pancreatic and colon-cutaneous 
fistula
Significant decrease of the effluent 
amount from the 4th day of use 5/B
Topical  phenytoin 
treatment in bimaxillary 
osteomyelitis secondary 
to infantile osteopetrosis: 
report of a case(21)
2006
Turkey Case study/N1
Macerated
pill apllied in a thin layer of 
20mg/cm2 and steryle gauze 1x/
day for 
2 weeks in bone exposition in 
oral cavity for osteomyelitis
Granulation and covering of bone 
exposure in 10 days 5/A
Phenytoin as a novel anti-
vitiligo weapon(22)
2005
Iran
Expert opinion /
hypothesis
Unspecified topic formula used 
in vitiligo lesions
Phenytoin would act by stimu-
lating melanocytes.  Animal 
experiments are suggested to test 
the hypothesis
6/A
The scientific production analyzed is characterized by 
the investigation of the healing potential of phenytoin by 
applying macerated pills directly on the wound, or the so-
lution obtained from macerated pills or intravenous solu-
tion, both diluted in saline at a concentration of 5 or 10 
mg/mL as shown in Table 1. Cream, ointment, alginate, 
lotion and aerosol were also other methods of application 
presented in the scientific production analyzed, although 
less frequently. 
The clinical applicability of phenytoin for the pur-
pose of healing wounds occurred primarily in diabetic 
foot and venous ulcers, followed by pressure and lep-
rosy ulcers. The other lesions were: osteomyelitis in 
the oral cavity, pyoderma gangrenosum, radiodermitis 
grade III, and those resulting from excision of melano-
cytic nevi.
Overall, the studies were incomplete when describ-
ing how the phenytoin application was applied in the RCT, 
and the quality of methodological designs is still predomi-
nantly low, as was indicated in the pioneering work of 
Shaw and colleagues(3).
diScUSSion
Benefits from the use of phenytoin were associated 
with increased granulation tissue, angiogenesis, and de-
creasing of wound size. In cases when the drug was used 
systemically for the management of fistulas, there was a 
significant decrease of the effluent flow - which suggests 
a likely decline in the size of the fistulas that can be justi-
fied by the anatomic healing process, probably induced 
by phenytoin(20).
Although the mechanisms by which phenytoin heals 
human tissues are unclear, in vitro studies in laboratory 
animals and in human histopathology have contributed 
some information to the understanding of this phenom-
enon, by demonstrating stimulatory action of the drug on 
fibroblasts and collagen synthesis, cellular remodeling, in-
hibition of collagenase, and acceleration of autocrine and 
paracrine activity of growth factors through biochemical 
regulation of cell receptors involved(3-4,8) and significant 
lymphocyte activation(20).
167Rev Esc Enferm USP2014; 48(1):162-9www.ee.usp.br/reeusp/
Scientific production on the applicability of 
phenytoin in wound healing
Firmino F, Almeida AMP, Silva RJG, Alves GS, 
Granadeiro DS, Penna LHG
It is noteworthy that studies of moderate to strong 
evidence pointed to the analgesic effects of this drug 
for wounds(10), and their authors mentioned the use of 
phenytoin as a secure application(10,12,15), important factors 
when one is concerned about systemic absorption that 
application of topical phenytoin may trigger.
In terms of comparisons, it is emphasized that topical 
phenytoin showed healing potential higher than saline, 
although lower than hydrocolloid(13). This fact makes the 
use of phenytoin as a healing agent attractive to health 
services devoid of greater resources for the acquisition of 
high-tech curative materials.
The scientific production on the healing potential 
of phenytoin is characterized by research on wounds 
that are classic problems for generating costs to the 
public system of global health, exacerbated in develo-
ping countries. Again it is important to consider that this 
drug was considered safe, inexpensive and effective in 
wound healing by several researchers considered in this 
integrative review(4,8-12,16-17,19,21).
However, further research should be performed to 
fill in knowledge gaps on the topic. One example is that, 
notoriously, the same author who published a level-1 
evidence study with inconclusive results regarding the 
application of the product on wounds, could not support 
the use of phenytoin as a healing product in diabetic foot 
ulcers when doing an experiment with evidence level 2 
using alginate formulation, unprecedented in the scienti-
fic literature on the subject. However, the author did not 
discuss this preference(14).
Surprisingly, phenytoin has been systemically used for 
the purpose of healing fistulas of the gastrointestinal tract, 
with encouraging results, although supported by weak re-
search evidence and therefore with low strength of recom-
mendation(20). However, it is a piece of information of inte-
rest to the field of oncology, including the use of phenytoin 
in healing radiodermitis grade III(4). Another study, not in-
cluded in this review because it was not available at the 
time of the search in the indexed databases, investigated 
the use of phenytoin 0.5% for mouthwash in patients su-
ffering from oral mucositis, resulting in improved quality of 
life of the group that received intervention(23).
The use of topical phenytoin in the form of 100 mg 
macerated pills diluted with 5 mL of 0.9% saline solution, 
applied 12/12 hr on a stage-4 pressure ulcer in the sacral 
region on a 50-year-old patient confined to bed for multi-
ple sclerosis sequelae, was performed by Brazilian physi-
cians and medical students in the northern region of the 
country. They reported that in 72 days the ulcer was com-
pletely filled with granulation tissue(24). This was a study 
approved by the Research Ethics Committee with eviden-
ce level 5, with degree of recommendation 5A. But this 
study was also not included in this review because it was 
not available in the indexed databases.
In the Middle East, spray phenytoin is available for 
wound healing, a product known as Healosol Spray: 
Wound Healing Promoter. Produced by the pharmacolo-
gical company ACODIMA (Arab Company for Drug Indus-
tries Medical Appliances), it has as one of its indications 
the use in burn wounds(25), which again refers to the appli-
cability of phenytoin in radiodermatitis burns, like studies 
number 4 and 11 of this review.
In Jordan in 2012, a preclinical study conducted on la-
boratory animals was published investigating the poten-
tial for wound healing of ethosuximide, barbituric acid 
and phenobarbital due to their structural similarity with 
phenytoin. The authors concluded that ethosuximide has 
clinical potential for the treatment of chronic wounds like 
phenytoin(26), making new hypotheses emerge from clini-
cal research in the field of healing of tissue injuries. It can 
be inferred that researchers have begun to investigate the 
healing potential of drugs similar to phenytoin.
The formulation of phenytoin solution from pills, cap-
sules or intravenous use is inconvenient for topical use 
because of low solubility and high pH (around 12), whi-
ch may have stinging and burning sensations as adver-
se effects(4,21). Hence the importance of the use of more 
specific formulations. In this sense, the Pharmacy School 
of the Royal College of Surgeons in Ireland - RCSI - has re-
searched formulations that may provide greater solubili-
ty of phenytoin with a pH around 7-8 to be administered 
to wounds(27).
The global organization of pharmacovigilance – the US 
Food and Drug Administration - known by the acronym 
FDA, has approved the use of originally systemic products 
for the topical treatment of wounds, including anesthe-
tics, antibiotics, and growth factors. In order to describe 
such situations in which a product is used for other pur-
poses than those indicated in the package insert, the term 
off-label prescription medication(28) was created.
Misoprostol, lidocaine, nifedipine, gentamicin and me-
tronidazole are examples of drugs being prescribed to tre-
at wounds in cream formulations, macerated pills, gel and 
spray, using the concept that can be called, in Brazil, off-la-
bel prescribing(28-29). It is a controversial practice, although 
it exists in our environment, such as the use of substances 
based on essential fatty acids (EFA) widely used as hea-
ling wounds, but still lacking quality studies to support use 
regarding safety and efficacy issues(30). The FDA accepts 
clinical studies that support the safety and efficacy of the 
applicability of the drugs in off-label uses, as well as the 
National Health Surveillance Agency - ANVISA – the regu-
latory agency in Brazil, which opens promising fields for 
research.
concLUSion
The integrative literature review performed in this stu-
dy concluded that topical phenytoin has strong evidence 
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of beneficial effects on the healing process in venous, pressu-
re, diabetic foot, leprosy, pyoderma gangrenosum ulcers and 
bed preparation for grafting. However, the studies conduc-
ted have moderate to low quality. More robust studies which 
support the use of phenytoin protocol as another option of 
healing agent in clinical practice are necessary.
Considering the way as scientific production presented the 
healing potential of phenytoin, the importance of incentives 
to produce studies that show its potential indications in the he-
aling process are needed, which will greatly contribute to the 
revision and updating of care measures developed by nursing 
and other areas of healthcare, technology and innovation.
REFEREncES
1. Hasamnis AA, Mohanty BK, Patil S. Evaluation of wound hea-
ling effect of topical phenytoin on excisional wound in albino 
rats. J Young Pharm. 2010;2(1):59-62.
2. Arya R, Gulati S. Phenytoin-induced gingival overgrowth. Acta 
Neurol Scand. 2012; 125(3):149-55.
3. Shaw J, Hughes CM, Lagan KM, Bell PM. The clinical effect of 
topical phenytoin on wound healing: a systematic review. Br J 
Dermatol. 2007;157(5):997-1004.
4. Firmino F. Potencial terapêutico da fenitoína na cicatrização de 
radiodermites. Esc Anna Nery Rev Enferm. 2007;11(1):143-9.
5. Souza MT, Silva MD, Carvalho R. Revisão integrativa: o que é e 
como fazer. Einstein. 2010;8(1 Pt 1):102-6. 
6. Soares BGO. Prática de enfermagem baseada em vidências. 
In: Bork AMT. Enfermagem baseada em evidências. Rio de Ja-
neiro: Guanabara Koogan; 2005. p. 3-13.
7. Langan SM, Williams HC. A systematic review of randomized 
controlled trials of treatments for inherited forms of epider-
molysis bullosa. Clin Exp Dermatol. 2008; 34(1):20-5.
8. Chauhan MBBS, Rasheed A, Pandley SS, Shukla MS. Nonhea-
ling wounds: a therapeutic dilemma. Int J Low Extrem Woun-
ds. 2003;2(1):40-5.
9. Hokkam E, El-Labban G, Shams M, Rifaat S, El-Mezaien M. The 
use of topical phenytoin for healing of chronic venous ulcera-
tions. Int J Surg. 2011;9(4):335-8.
10. Carneiro PM, Nyawawa ET. Topical phenytoin versus eusol in 
the treatment of non-malignang chronic leg ulcers. East Afr 
Med J. 2003;80(3):124-9.
11. Bhatia A, Nanda S, Gupta U, Gupta S, Reddy BSN. Topical 
phenytoin suspension and normal saline in the treatment of 
leprosy trophic ulcers: a randomized, double-blind, compa-
rative study. J Dermatolog Treat. 2004;15(5):321-7.
12. Subbanna PK, Shanti MFX, George J, Tharion G, Neelakantan 
N, Durai S, et al. Topical phenytoin solution for treating pres-
sure ulcers: a prospective, randomized, double-blind clinical 
trial. Spinal Cord. 2007;45(11):739-43.
13. Hollisaz MT, Khedmat H, Yari F. A randomized clinical trial 
comparing hydrocolloid, phenytoin and simple dressings for 
the treatment of pressure ulcers [ISRCTN33429693]. BMC 
Dermatol. 2004;4(1):18.
14. Shaw J, Hughes M, Lagan KM, Stevensont MR, Irwin CR, 
Bell PM. The effect of topical phenytoin on healing in dia-
betic foot ulcers: a randomized controlled trial. Diabet Med. 
2011;28(10):1154-7.
15. Fonseka HFS, Ekanayake SMB, Dissanayake M. Two percent 
topical sodium solution in treating pyoderma gangrenosum: 
a cohort study. Int Wound J. 2010;7(6):519-23.
16. Pereira CAZ, Alchorne AO. Assessment of the effect of 
phenytoin on cutaneous healing from excision of mela-
nocytic nevi on the face and on the back. BMC Dermatol. 
2010;10:7.
17. Younes N, Albsoul A, Badran D, Obedi S. Wound bed pre-
paration with 10 percent phenytoin ointment increases the 
take of split-thickness graft inlarge diabetic ulcers. Dermatol 
Online J. 2006;12(6):5.
18. El-Nahas M, Gawish H, Tarshoby M, State O. The impact of 
topical phenytoin on recalcitrant neuropathic diabetic foot 
ulceration. J Wound Care. 2009;18(1):33-7.
19. Pitiakoudis M, Giatromanolak A, Iliopoulos L, Tsaroucha 
AK, Simopoulos C, Piperidou C. Phenytoin-induced lym-
phocytic chemotaxis, angiogenesis and accelerated healing 
of decubitus ulcer in a patient with stroke. J Int Med Res. 
2004;32(2):201-5.
20. Jaber S, Rihy Z, Joseph R, Al-Khayat M. Does phenytoin im-
prove the healing of gastrointestinal fistulas? Case Rep Gas-
troenteral. 2011;5(1)52-5.
21. Er N, Kasaboglu O, Atabek A, Oktemer K, Akkocaoglu M. 
Topical phenytoin treatment in binaxillary osteomyelitis se-
condary to infantile osteopetrosis: report of a case. J Oral 
Maxillofac Surg. 2006;64(7):1160-4.
22. Namazi MR. Phenytoin as a novel anti-vitiligo weapon. J 
Atoimmune Dis. 2005;2:11.
23. Baharvand M, Sarrafi M, Alavi K, Jalali Moghaddam E. Effi-
cacy of topical phenytoin on chemotherapy-induced oral 
mucositis; a pilot study. Daru. 2010;18(1):46-50.
24. Santos Junior EP, Batista RRAM, Oliveira RB, Bezerra NMF, 
D’Albuquerque e Castro LF. O uso de fenitoína na cicatriza-
ção de úlcera por pressão: desafio terapêutico. Rev Cient 
ITPAC [Internet]. 2011;4(2):4-9. [2012 maio 7). Disponível 
em: http://www.itpac.br/hotsite/revista/artigos/42/7.pdf
169Rev Esc Enferm USP2014; 48(1):162-9www.ee.usp.br/reeusp/
Scientific production on the applicability of 
phenytoin in wound healing
Firmino F, Almeida AMP, Silva RJG, Alves GS, 
Granadeiro DS, Penna LHG
correspondence addressed to:  Flávia Firmino
Institut  Nacional e Câ cer, Hospital de Câncer 4, Cuidados Paliativos
Rua Visconde de Santa Isabel, 274 
CEP  20560-120 – Rio de Janeiro, RJ, Brazil
25. ACDIMA International. Medical aerosols [Internet]. 2012 
[cited 2012 May 07]. Available from: http://www.acdimatra-
ding.com 
26. Ajwee DM, Disi AM, Qunaibi EA, Taha MO. Ethosuximide 
and Phenobarbital Promote Wound Healing via Enhancing 
Collagenization. Chem Biol Drug Des. 2012; 79(1):137-42.
27. Kelly JG. Technology Transfer Manager. Royal College of 
Surgeons in Ireland. RCSI. Topgel. Irlanda patent PCT/ EP 
2005/008344. 2005. Available from: http://www.docstoc.
com/docs/47619418/A-New-Product-for-the-Treatment-of-
Chronic-Wounds 
28. Smith RG. Off-label use of prescription medication: a litera-
ture review. Wounds. 2010;22(4):78-86.
29. Brasil. Ministério da Saúde; Secretaria de Ciência, Tecnolo-
gia e Insumos Estratégicos, Comissão Nacional de Incorpo-
ração de Tecnologias no SUS. Uso off label: erro ou necessi-
dade? Rev Saúde Pública [Internet]. 2012 [citado 2013 jun. 
06];46(2):398-9. Disponível em: http://www.scielo.br/pdf/
rsp/v46n2/it_decit.pdf
30. Ferreira AM, Souza BMV, Rigotti MA, Loureiro MRD. The 
use of fatty acids in wound care: an integrative review of 
the Brazilian literature. Rev Esc Enferm USP [Internet]. 2012 
[cited 2013 June 06];46(3):752-60. Available from: http://
www.scielo.br/pdf/reeusp/v46n3/en_30.pdf 
